{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:27:24Z","timestamp":1785583644254,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,6]]},"DOI":"10.7759\/cureus.81806","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T21:32:40Z","timestamp":1743975160000},"source":"Crossref","is-referenced-by-count":2,"title":["Late-Onset Hypophysitis Induced by Nivolumab in Advanced Esophageal Squamous Cell Carcinoma"],"prefix":"10.7759","author":[{"given":"Oumaima","family":"Lamsyah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intissar","family":"Belrhali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousra","family":"Al Harrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihame O","family":"Lkhoyaali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Errihani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2022.06.004","article-title":"News in gastrointestinal radiotherapy: the esophageal cancer","volume":"26","author":"Qu\u00e9ro L","year":"2022","unstructured":"Qu\u00e9ro L, Besnard C, Guillerm S, Hennequin C. News in gastrointestinal radiotherapy: the esophageal cancer. Cancer Radiother. 2022, 26:875-8. 10.1016\/j.canrad.2022.06.004","journal-title":"Cancer Radiother"},{"key":"ref2","article-title":"Nivolumab induced multiple endocrinopathies; adrenal insufficiency and primary hypothyroidism in a patient with stage IV gastric cancer-a case report","volume":"5","author":"Abdelmasih R","year":"2021","unstructured":"Abdelmasih R, Abdelmaseih R, Gandhi R. Nivolumab induced multiple endocrinopathies; adrenal insufficiency and primary hypothyroidism in a patient with stage IV gastric cancer-a case report. Jr Endo Soc. 2021, 5:A145.","journal-title":"Jr Endo Soc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al.. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir CA","year":"2021","unstructured":"Muir CA, Clifton-Bligh RJ, Long GV, et al.. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab. 2021, 106:e3704-13. 10.1210\/clinem\/dgab263","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.836859","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel S","year":"2022","unstructured":"Jessel S, Weiss SA, Austin M, et al.. Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function. Front Oncol. 2022, 12:836859. 10.3389\/fonc.2022.836859","journal-title":"Front Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette J","year":"2019","unstructured":"de Filette J, Andreescu CE, Cools F, et al.. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res. 2019, 51:145-56. 10.1055\/a-0843-3366","journal-title":"Horm Metab Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje A","year":"2019","unstructured":"Faje A, Reynolds K, Zubiri L, et al.. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019, 181:211-9. 10.1530\/EJE-19-0238","journal-title":"Eur J Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0101","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"15","author":"Castillero F","year":"2019","unstructured":"Castillero F, Castillo-Fern\u00e1ndez O, Jim\u00e9nez-Jim\u00e9nez G, et al.. Cancer immunotherapy-associated hypophysitis. Future Oncol. 2019, 15:3159-69. 10.2217\/fon-2019-0101","journal-title":"Future Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune hypophysitis","volume":"26","author":"Caturegli P","year":"2005","unstructured":"Caturegli P, Newschaffer C, Olivi A, et al.. Autoimmune hypophysitis. Endocr Rev. 2005, 26:599-614. 10.1210\/er.2004-0011","journal-title":"Endocr Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luad135","article-title":"Nothing great comes without its risks: a rare case of pembrolizumab-induced hypophysitis","volume":"2","author":"Fernando A","year":"2024","unstructured":"Fernando A, Mittal A, Cheema R. Nothing great comes without its risks: a rare case of pembrolizumab-induced hypophysitis. JCEM Case Rep. 2024, 2:luad135. 10.1210\/jcemcr\/luad135","journal-title":"JCEM Case Rep"},{"key":"ref11","unstructured":"Opdivo INN-Nivolumab. Summary of product characteristics. (2024). Accessed: April 6, 2025: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez E","year":"2016","unstructured":"Gonz\u00e1lez-Rodr\u00edguez E, Rodr\u00edguez-Abreu D. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016, 21:804-16. 10.1634\/theoncologist.2015-0509","journal-title":"Oncologist"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang LS","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, et al.. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019, 40:17-65. 10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2018.09.002","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"45","author":"Solinas C","year":"2018","unstructured":"Solinas C, Porcu M, De Silva P, et al.. Cancer immunotherapy-associated hypophysitis. Semin Oncol. 2018, 45:181-6. 10.1053\/j.seminoncol.2018.09.002","journal-title":"Semin Oncol"},{"key":"ref16","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. Jr Clin Onc. 2018, 36:1714-1768.","journal-title":"Jr Clin Onc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/351301-late-onset-hypophysitis-induced-by-nivolumab-in-advanced-esophageal-squamous-cell-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T21:32:55Z","timestamp":1743975175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/351301-late-onset-hypophysitis-induced-by-nivolumab-in-advanced-esophageal-squamous-cell-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,6]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.81806","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,6]]}}}